Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024)

被引:0
作者
Woo, Emily Jane [1 ]
Miller, Elaine R. [2 ]
Stroud, Erin [2 ]
机构
[1] US FDA, Ctr Biol Evaluat & Res, Off Biostat & Pharmacovigilance, 10903 New Hampshire Ave, Silver Spring, MD 20903 USA
[2] CDCP, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Immunizat Safety Off, 1825 Century Ctr 1600 Clifton Rd NE,Mailstop H 16-, Atlanta, GA 30329 USA
关键词
Live attenuated influenza vaccine; Syncope; Injury; Adverse event;
D O I
10.1016/j.vaccine.2024.126290
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vasovagal syncope, or fainting, can be triggered by various stimuli, including medical procedures. Syncope after vaccination has been reported, most commonly among adolescents, and can result in injuries. Using the Vaccine Adverse Event Reporting System (VAERS), we reviewed and summarized reports of syncope after live attenuated influenza vaccine, intranasal (LAIV) administered as the sole vaccine (i.e., no concomitant injections). From June 17, 2003 (date of LAIV licensure in the US) through May 31, 2024, VAERS received 50 reports of syncope after LAIV. Nearly half (23; 46 %) pertained to individuals 10-19 years of age. While the vast majority of reports (35; 70 %) did not describe any injuries, 15 people (30 %) were injured, most commonly by falling and hitting their head or face. Twenty-two people (44 %) required evaluation in the emergency department or doctor's office, including an individual who lost consciousness while he was driving home from the vaccination appointment. He did not report any injuries, but the car was severely damaged. Nearly three-quarters of people (37; 74 %) developed syncope within 15 min after vaccination, but fewer than half of reports (24; 48 %) stated that the patient had waited in the observation area for at 15 min. Based on approximately 111.9 million doses of LAIV distributed in the US during the same time period, the reporting rate is approximately 0.4 per million doses, suggesting that syncope following LAIV is rare. The information summarized here may enable clinicians, patients, and caregivers to make a more informed decision regarding preventing injuries that may occur following LAIV-related syncope.
引用
收藏
页数:4
相关论文
共 20 条
  • [1] American Academy of Pediatrics, 2024, Red book: 2024-2027 report of the committee on infectious diseases, V33rd
  • [2] [Anonymous], 2003, FluMist approval letter
  • [3] [Anonymous], 2024, CODE FEDERAL REGULAT
  • [4] [Anonymous], 2024, FluMist package insert
  • [5] [Anonymous], 2012, FluMist Quadrivalent approval letter
  • [6] Syncope after immunization
    Braun, MM
    Patriarca, PA
    Ellenberg, SS
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 1997, 151 (03): : 255 - 259
  • [7] The safety of live attenuated influenza vaccine in children and adolescents 2 through 17years of age: A Vaccine Safety Datalink study
    Daley, Matthew F.
    Clarke, Christina L.
    Glanz, Jason M.
    Xu, Stanley
    Hambidge, Simon J.
    Donahue, James G.
    Nordin, James D.
    Klein, Nicola P.
    Jacobsen, Steven J.
    Naleway, Allison L.
    Jackson, Michael L.
    Lee, Grace
    Duffy, Jonathan
    Weintraub, Eric
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (01) : 59 - 68
  • [8] DuMouchel W., 2001, KDD-2001. Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, P67, DOI 10.1145/502512.502526
  • [9] Grohskopf LA, 2022, MMWR-MORBID MORTAL W, V71, P1
  • [10] IOM (Institute of Medicine), 2011, Adverse effects of vaccines: Evidence and causality